Pfizer, BioNTech win FDA approval for XFG-adapted COVID-19 vaccine in high-risk US adults

Reuters2026/08/27 20:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Pfizer’s supplemental filing for an XFG-adapted COMIRNATY COVID-19 shot for the 2026-2027 season.
Authorization covers adults 65+ plus ages 5-64 with at least one high-risk underlying condition.
Shipments start immediately, supporting near-term seasonal demand in the U.S. market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271630PRIMZONEFULLFEED1001259770) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer, BioNTech win FDA approval for XFG-adapted COVID-19 vaccine in high-risk US adults

You may also like

Crypto prices